Bozicevic, Field & Francis LLP
Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration
It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.
The Board of Trustees of the Leland Stanford Junior University
A A A A A A A A C A A A A A A
A61P A61P A61K A61P A61K A61P A61K A61K C07F A61P A61P A61P A61K A61K A61K
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Richard James P. David Alvin Christopher Jeffrey Paul Clifford Brian Stanley
Decreau Collman Tyvoll Barile Herrmann Bull